Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ACP-501 · 1 trial · 2 indications
Safety and tolerability of a single dose of ACP-501 as determined by adverse event reporting, clinical laboratory results, vital signs, physical examination, and electrocardiograms (ECGs).
| Arm | Type | Description |
|---|---|---|
| ACP-501 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ACP-501 | DRUG | A single dose infusion |
Inclusion Criteria: * A history of stable documented CAD * Currently non-smoking males and females ages 30 to 85 years inclusive. o Female subjects of child-bearing potential (neither pregnant nor breast-feeding) must be using adequate birth control during study conduct. * Chronic concomitant me...
ACP-501 is an investigational small molecule being developed for the treatment of Coronary Artery Disease. It is intended to address atherosclerosis, a condition characterized by the buildup of plaque in the arteries. The drug is currently in Phase 1 clinical development, meaning it is still being tested for safety and tolerability in humans.
ACP-501 is being developed by AstraZeneca PLC, a multinational pharmaceutical company. AstraZeneca is listed on the stock exchange under the ticker symbol AZN. The company is conducting clinical research to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ACP-501 in patients with Coronary Artery Disease.
ACP-501 is in Phase 1 clinical development. A Phase 1 trial has been completed, which enrolled 16 participants with Coronary Artery Disease. The study was not randomized, double-blind, or controlled, and it focused on assessing the drug's safety, tolerability, and how the body processes it. The drug is not yet approved and remains investigational.
ACP-501 has one completed clinical trial registered under NCT01554800. The trial, titled "Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease," was a Phase 1 study conducted in the United States. It enrolled 16 participants aged 30 years and older, all with Coronary Artery Disease or Atherosclerosis.
ACP-501 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. A Phase 1 trial has been completed, but the drug has not yet progressed through the later phases of clinical testing required for regulatory approval. As such, it is not available for commercial use and is only being studied in clinical research settings.